Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

-- Reported Unaudited Total Revenues of Between $72 Million -$74 Million in the Fourth Quarter of 2023 -- -- Company Ends 2023 with a Cash Position of $321 Million and Delivered Full-Year Positive Cash Flow of ~$10 Million -- -- 2024 Key Priorities Include Accelerating Revenue in Key European Launch Markets, Retaining IPE Market Leadership in the US and Maximizing Patient Uptake in Rest of World (RoW) Through Partnerships -- -- Company Announces Plan to Initiate Share Repurchase Program of Up to $50 Millio ...